Status:
COMPLETED
A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct Cancers
Lead Sponsor:
Mauna Kea Technologies
Collaborating Sponsors:
Cellvizio Inc.
Emissary International LLC
Conditions:
Pancreatic Cancer
Bile Duct Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This registry will collect data from patients routinely undergoing an ERCP and Cellvizio endomicroscopy procedure (and optionally an additional cholangiopancreatoscopy procedure) due to suspected panc...
Detailed Description
This is a registry study to collect high quality longitudinal data from patients with suspected or indeterminate pancreaticobiliary pathology who are undergoing an ERCP with Cellvizio probe-based endo...
Eligibility Criteria
Inclusion
- Male or female \> 18 years of age
- Willing and able to comply with Registry procedures and provide written informed consent to participate in the Registry
- Indicated for ERCP and/or cholangiopancreatoscopy
- Indeterminate or suspected biliary and/or pancreatic stricture, mass, or neoplasm
Exclusion
- Subjects for whom ERCP procedures are contraindicated
- Known allergy to fluorescein dye
Key Trial Info
Start Date :
November 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00779688
Start Date
November 1 2008
End Date
October 1 2010
Last Update
February 10 2011
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado Hospital
Aurora, Colorado, United States, 80045
2
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
3
New York Presbyterian Hospital/Columbia University Medical Center
New York, New York, United States, 10032
4
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213